Clinical trial

Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.

NCT00740584

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention 3% SPL7013 Gel (VivaGel) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1, PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2008-08-01

PhasePHASE1 / PHASE2

Conditions

HIV Infectionsunresolved

HSV-2 Genital Herpesunresolved

Interventions

3% SPL7013 Gel (VivaGel)DRUG

Sponsors & collaborators

Starpharma Pty Ltdlead sponsor

National Institute of Allergy and Infectious Diseases (NIAID)collaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00740584 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.